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Introduction: Oncogenic anaplastic lymphoma kinase (ALK) gene 
rearrangements in non–small-cell lung carcinomas (NSCLC) provide 
the basis for targeted therapy with crizotinib and other specific ALK 
inhibitors. Treatment eligibility is conventionally determined by the 
Food and Drug Administration–approved companion diagnostic flu-
orescence in situ hybridization (FISH) assay on  paraffin-embedded 
tissue (PET). On limited samples such as fine needle aspiration–
derived cytoblocks, FISH for ALK is often uninformative. FISH 
performed on liquid-based ThinPrep slides (ThinPrep-FISH) may 
represent a robust alternative.
Methods: Two hundred thirty cytology samples from 217 patients 
with advanced NSCLC, including a consecutive series of 179 speci-
mens, were used to generate matched ThinPrep slides and paraffin 
cytoblocks. The same ThinPrep slides used for cytologic diagnosis 
were assessed by standard ALK break-apart two-color probe FISH, 
after etching of tumor areas. Ultrasensitive ALK immunohistochem-
istry (IHC) on corresponding cytoblocks [D5F3 antibody, OptiView 
signal amplification] served as the reference data set.
Results: ThinPrep-FISH ALK signals were robust in 228 of 230 
cases and not compromised by nuclear truncation inherent in 
 paraffin-embedded tissue–FISH; only two samples displayed no sig-
nals. Nine of 178 informative cases (5%) in the consecutive series 
and 18 of 228 informative cases (7.8%) overall were ALK rearranged 
by ThinPrep-FISH. In 154 informative matched ThinPrep-FISH and 
cytoblock-IHC samples, 152 were concordant (10, 6.5% ALK sta-
tus positive; 142, 92.2% ALK status negative), and two (1.3%) were 
ThinPrep-FISH positive but IHC negative (sensitivity 100%, speci-
ficity 98.6%, overall agreement 98.7%).
Conclusion: Detection of ALK gene rearrangements in liquid cytol-
ogy ThinPrep slides derived from patients with NSCLC can be confi-
dently used for clinical ALK molecular testing.
Key Words: Anaplastic lymphoma kinase, Fluorescence in situ 
hybridization, ThinPrep, Non–small-cell lung cancer, Lung cancer, 
Adenocarcinoma.
(J Thorac Oncol. 2014;9: 464–468)
Lung cancer is the second most common overall malig-nancy in the United States and, despite improved detection 
and treatment, it remains the leading cause of cancer-related 
death in men and women worldwide.1 Lung cancer is classi-
cally divided into small-cell and non–small-cell types based 
on morphology and clinical features. With recent advances 
in molecular pathogenesis and the discovery of specific 
targetable genetic alterations in certain lung carcinomas, 
molecular classification and genotyping have now become 
essential for optimal therapeutic management. Non–small 
cell lung carcinomas (NSCLCs) represent approximately 
80% of lung cancers and are further classified into adeno-
carcinoma (40%–50%), squamous cell carcinoma (30%) and 
large-cell carcinoma (9%).2 A subset of NSCLC, primarily 
adenocarcinomas, exhibit mutations of the epidermal growth 
factor receptor gene that confer sensitivity to tyrosine kinase 
inhibitors. Targeted therapies with such inhibitors have been 
shown to improve the otherwise dismal survival in patients 
with tumors harboring epidermal growth factor receptor gene 
activating mutations.3
The anaplastic lymphoma kinase (ALK) gene encodes a 
receptor tyrosine kinase that is normally not expressed in lung 
cells. Approximately 5% of NSCLCs harbor ALK gene rear-
rangements, most commonly in the form of a small intrachro-
mosomal inversion, inv(2)(p21;p23), resulting in the fusion of 
ALK with echinoderm microtubule associated protein like 4 
gene.4 The ALK/echinoderm microtubule associated protein 
like 4 fusion produces an abnormal, constitutively active chi-
meric protein kinase with oncogenic properties.5,6 Targeted 
ALK tyrosine kinase inhibitors have proven anticancer 
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activity, with crizotinib showing a good clinical response in 
advanced NSCLC patients harboring ALK rearrangements.7
Although relatively uncommon in NSCLC, the presence 
of ALK rearrangements has major therapeutic implications, 
and thus needs to be assessed through an accurate, reproduc-
ible, and accessible diagnostic test. The U.S. Food and Drug 
Administration approved an in vitro diagnostic class fluores-
cence in situ hybridization (FISH) test as a companion diag-
nostic tool for crizotinib-based treatment eligibility (Abbott 
Molecular Vysis [AMV], Des Plaines, IL). As a consequence, 
FISH is currently considered the definitive standard for ALK 
status testing and it can be performed on paraffin-embedded 
tissue material (PET). The commercial break-apart FISH 
format consists of red and green probes that flank the highly 
conserved translocation breakpoint within ALK gene. Normal 
cells exhibit yellow fusion signals whereas neoplastic cells har-
boring ALK rearrangements show split red and green signals. 
A case is interpreted as ALK-positive by FISH when 15% or 
more tumor cell nuclei demonstrate isolated green and red sig-
nals, or isolated red signals, among 50 tumor nuclei scored.8
With the current rising availability and emphasis on 
minimally invasive diagnostic procedures such as endobron-
chial ultrasound (EBUS), testing for ALK rearrangements by 
FISH is increasingly attempted on small specimens, including 
biopsy samples or paraffin cytoblocks prepared from fine nee-
dle aspiration (FNA) samples. Indeed, at our institution, FNA 
samples are a common form of diagnostic material, especially 
for patients with locally advanced disease for which the EBUS 
FNA is performed for both diagnosis and staging—EBUS 
FNA specimens comprise approximately a third of the samples 
submitted for molecular testing at our institution. Notably, the 
data submitted by AMV to the Food and Drug Administration 
did not include any paraffin cytoblocks or other cytopathol-
ogy material.7 In certain cases, that is, those of patients with 
 late-stage disease, small FNA specimens may be the only mate-
rial available for testing. This issue has been recognized, and 
the latest guidelines from the College of American Pathologists 
stipulate that cytology specimens consisting of paraffin cytob-
locks and smears are also suitable material for molecular test-
ing, including  ALK-FISH.9 As previously reported by others, 
as well as from our own experience, ALK-FISH performed 
on paraffin cytoblock slides has a high rate of failure (>30%) 
because of either insufficient material for cytoblock prepara-
tion or insufficient tumor cells in the cytoblock for informa-
tive FISH results.10 The latter seems to be the case even though 
abundant tumor cells are present on the ThinPrep slide used 
for cytopathologic diagnosis. Even with enough available 
material, ALK-FISH on paraffin samples may be difficult to 
interpret because of signal loss by section artifacts, target DNA 
integrity, or incomplete penetration of probes into the tissue.
Recent reports, including one from our institution, have 
described the value of ultrasensitive immunohistochemistry 
(IHC) in detecting ALK status. ALK-IHC with novel engineered 
antibodies and secondary signal amplification showed high 
concordance with ALK-FISH on both tissue11–13 and cytology 
material.14,15 Although IHC is more frequently informative on 
cytoblocks than FISH, it is still not an alternative in cases with 
limited or no PET material. In such cases, the only available 
material may be the slide used for cytopathologic diagnosis in 
the form of smear or liquid-based preparation such as ThinPrep, 
which may represent a valuable resource for testing ALK status.
Here we assessed the diagnostic value of ALK-FISH 
performed on ThinPrep slides prepared from FNA biopsies for 
detecting ALK status in an NSCLC case series at our institu-
tion. We demonstrate that ThinPrep-FISH can reliably detect 
ALK gene rearrangements in NSCLC and has a very high con-
cordance with ultrasensitive ALK-IHC, warranting its routine 
use for clinical ALK molecular testing in NSCLCs.
MATERIALS AND METHODS
Specimens
The study included 230 samples derived from trans-
bronchial FNA (164), extrapulmonary FNA (chest wall, neck, 
other sites; 16), bronchial brush (20), pleural fluid (24), peri-
cardial fluid (5), and peritoneal fluid (1) from 217 patients with 
advanced NSCLCs that were clinically referred for ALK test-
ing at our institution (Cleveland Clinic Foundation). The cohort 
included a consecutive series of 179 samples collected from 
174 patients between December 2012 and August 2013. The 
samples were collected in CytoLyt (Cytyc Corp., Boxborough, 
MA) and centrifuged to generate cell pellets. Material from the 
cell pellets was divided for preparation of ThinPrep slides by 
using T200 or T500 processors (Hologic, Bedford, MA) and 
cytoblocks using a Cellient cell block processor (Hologic).
Fluorescence In Situ Hybridization 
FISH for ALK rearrangements was performed on the 
ThinPrep slides using the AMV ALK Break Apart FISH Probe 
Kit with preanalytical and assay modifications previously 
detailed for ThinPrep-FISH to monitor recurrence of urothelial 
carcinoma.16,17 Specific areas with abundant tumor cells were 
etched with a diamond tip pen on the reverse side of the slide 
before removal of the cover slip and probe application. All areas 
of the ThinPrep slide were screened qualitatively and signals 
enumerated selectively for tumor cells based on 4′,6-diamid-
ino-2-phenylindole (DAPI) fluorescence pattern. To interpret 
the ThinPrep-FISH, the same cutoff of 15% positive cells was 
used as is specified for the in vitro diagnostic AMV probe set. 
Similarly, signal pattern classification was also based on the 
same criteria used for PET-FISH.
Immunohistochemistry
Automated IHC for ALK expression was performed on 
material from 211 available cytoblocks using the D5F3 antibody 
(a generous gift from Cell Signaling Technology, Danvers, MA), 
coupled with OptiView DAB IHC Detection Kit with Optiview 
signal amplification (a generous gift from Ventana Medical 
Systems, Tucson, AZ), and interpreted as either negative (no 
staining present) or positive (membranous staining present) as 
described previously.11,12
Statistical Analysis
The χ2 test was used to compare the proportions of 
uninformative samples between ThinPrep-FISH and IHC 
(graphPad Prism, graphPad Software).
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RESULTS
Our study included a total of 230 cytology samples from 
217 patients with advanced NSCLC clinically referred for 
ALK testing in the Cleveland Clinic Health System, including 
a consecutive series of 179 specimens. ThinPrep-FISH was 
performed on the ThinPrep slides used for the cytopathology 
diagnosis for all samples (Fig. 1A). Matched cytoblocks were 
available in 211 of 230 samples (92.6%) and were used for 
comparative ALK status testing (Table 1). ThinPrep-FISH was 
overall informative for 228 of 230 samples (99.1%) (178 of 
179 cases, 99.4%, in the consecutive series), with two sam-
ples displaying no signals for enumeration on the ThinPrep 
slides. ALK rearrangements were detected by ThinPrep-FISH 
on nine of 178 informative samples (5%) in the consecutive 
series and 18 of 228 informative samples (7.8%) overall. Of 
the 18  ALK-rearranged samples, seven demonstrated a typical 
positive pattern (isolated green and red signals accompanied 
by juxtaposed normal signal pairs) and 11 showed an atypical 
positive pattern (isolated red signals only accompanied by jux-
taposed normal signal pairs). A representative  ThinPrep-FISH 
image is shown in Figure 1B.
Because of the high failure rate of ALK-FISH on par-
affin cytoblock slides (>30% in our preliminary experience 
before the initiation of this study, data not shown), we chose 
to use ultrasensitive ALK-IHC as previously described11 on 
the available corresponding cytoblocks as the reference data 
set. Of the available 211 cytoblocks, 57 (27%) proved to have 
no material or insufficient tumor cells for evaluation despite 
abundant tumor cells being present on the ThinPrep slide.
Of 154 samples with informative paired ALK 
 ThinPrep-FISH and cytoblock-IHC results, 10 of 154 samples 
(6.5%) were ThinPrep-FISH positive and IHC positive for 
ALK rearrangements/expression (Fig. 1C), two of 154 sam-
ples (1.3%) were ThinPrep-FISH positive but IHC negative, 
and 142 of 154 samples (92.2%) were ThinPrep-FISH nega-
tive and IHC negative. Overall, ThinPrep-FISH showed 100% 
sensitivity, 98.6% specificity, and 98.7% overall agreement 
when compared with ultrasensitive D5F3 ALK-IHC (Table 2).
Importantly, ThinPrep-FISH was the sole informative 
analysis in a significant proportion of samples (74 of 228, 
32.4%) and revealed additional ALK-positive cases (6 of 74), 
which were missed by cytoblock analysis because of lack of 
material or insufficient tumor cells for interpretation.
DISCUSSION
The detection of ALK rearrangements in NSCLC 
is currently accomplished by most clinical laboratories 
using PET material testing by FISH as an Food and Drug 
Administration–approved companion in vitro diagnostic tool 
for determining treatment eligibility with the ALK inhibitor 
FIGURE 1.  Representative images of non–small-cell lung carcinoma positive for ALK rearrangements by ThinPrep-FISH 
 showing a typical positive pattern (A, ThinPrep-Papanicolaou 1000×; B, ThinPrep-FISH 1000×), and positive for ALK  expression 
by D5F3-IHC on the paraffin cytoblock (C, hematoxylin and eosin 400×; D, D5F3-IHC, 400×). FISH, fluorescence in situ 
 hybridization; ALK, anaplastic lymphoma kinase; IHC, immunohistochemistry. 
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crizotinib. Although considered a robust definitive standard 
test, ALK-FISH on PET material is not free of shortcom-
ings, including: challenging interpretation because of probe 
design truncation artifacts and frequent uninformative results 
resulting from insufficient tumor cell number. IHC with novel 
antibodies and modified detection protocols is emerging as a 
potential alternative for FISH, with sensitivity and specificity 
results approaching those of the latter.11–13 However, as with 
FISH, IHC may be of little use in cases with limited material, 
such as that obtained from cytology preparations derived from 
FNA biopsies.
Indeed, ALK status testing is requested with increasing 
frequency on small specimens or FNA cytopathology biopsy 
samples procured through minimally invasive procedures 
such as EBUS transbronchial needle aspiration. These proce-
dures are generally successful in rendering enough diagnostic 
material,18,19 and are preferred in cases with late-stage cancer 
not amenable for surgical treatment because of lower rate of 
complications. At our institution, the ThinPrep liquid-based 
cytology platform (Hologic, Bedford, MA) is the method of 
choice for processing FNA and body fluid specimens. Some 
of the advantages of this method include: minimal artifacts 
derived from air-drying and smear-crushing and homogenous 
cell enrichment with nearly 100% cell transfer to slide,20 
whereas criticism for this method is based on shrinkage arti-
facts21 and higher cost. The protocol involves generation of a 
cell pellet from the FNA sample collected in CytoLyt, which 
is then divided for the preparation of a ThinPrep slide used 
for diagnosis and of a paraffin cytoblock used for IHC and 
molecular testing.22 In a significant proportion of cases, the 
material obtained from an FNA procedure is not sufficient 
for cytoblock preparation and further molecular testing. Even 
more frequently in our experience, a significant proportion of 
the cytoblocks contain few if any recognizable tumor cells, 
despite the presence of a seemingly adequate initial cell pel-
let and abundant tumor cells on the ThinPrep slide used for 
diagnosis. This issue has also been reported by others23 and 
has been attributed to the inherent variability in the cytoblock 
preparation process likely resulting in nonuniform cell clump-
ing. Exhaustion of the cytoblock material after IHC workup 
for diagnostic purposes further limits additional molecular 
testing. Inadequacy of paraffin cytoblocks for molecular test-
ing is a problematic issue that can lead to undesirable treat-
ment delays or mistakes in a subset of cases and result in 
repeat procedures necessary to obtain additional material.
To our knowledge this is the first report showing 
the feasibility of ALK-FISH testing directly on ThinPrep 
 liquid-based cytology slides. In keeping with the most recent 
recommendations of the College of American Pathologists,9 
several reports described the use of cytologic material derived 
from minimally invasive procedures like EBUS for molecu-
lar testing in NSCLC.14,15,22,24–27 These studies involved limited 
series of cases with some making use of paraffin cytob-
locks for ALK testing by FISH or IHC,22,24,25 whereas others 
used Pananicolaou-stained smears directly for similar test-
ing.14,15,26,27 In these studies, IHC was highly concordant with 
FISH for ALK status, when performed on either cytoblock 
material or previously stained direct smears. The reported 
proportion of cases with uninformative FISH seemed to be 
higher for cytoblocks than that for the ThinPrep-FISH in our 
work.22,24,25 Our study included a large NSCLC cohort with 
available liquid-based cytology material for ALK status test-
ing by ThinPrep-FISH. The College of American Pathologists 
guidelines recommend that for ALK-FISH testing on cytology 
material, cytoblock-derived slides are preferred over smears 
for concerns of overlapping cells complicating the signal enu-
meration in the latter.9 Using ThinPrep slides for ALK-FISH 
testing can eliminate this concern as the cells are distributed 
in a monolayer, and may result in a higher proportion of infor-
mative cases.
Several advantages can be envisioned for perform-
ing ALK-FISH directly on ThinPrep slides as compared with 
slides derived from paraffin cytoblocks. In addition to the 
already mentioned superior adequacy for sufficient tumor, 
compared with PET sections, cytologic preparations such as 
ThinPrep allow assessment of the entire tumor cell nucleus, 
thus avoiding signal loss by section truncation artifacts or 
incomplete penetration of probes into the tissue, and provid-
ing more accurate signal counts. Furthermore, the etching of 
areas with abundant tumor directly on the ThinPrep slides at 
the time of diagnosis allows precise FISH probe enumeration 
in tumor cells without interference from normal cells. Indeed, 
TABLE 1.  Breakdown of Available and Informative Non–Small-Cell Lung Carcinoma Samples by Type and Test
Sample Type Total Available Informative by ThinPrep-FISH Informative by IHC Informative by ThinPrep-FISH and IHC
ThinPrep slide 230 228 N/A 154
Cytoblock 211 N/A 154
FISH, fluorescence in situ hybridization; IHC, immunohistochemistry. 
TABLE 2.  Correlation between ThinPrep-FISH and D5F3-
IHC on 154 Available Dual-Informative Non–Small-Cell Lung 
Carcinoma Samples
D5F3-IHC
TotalPositive Negative
ThinPrep-FISH Positive 10 2
Negative 0 142
154
Sensitivity 100% (95% CI: 0.65–1.00)
Specificity 98.6% (95% CI: 0.94–0.99)
Positive predictive value 83.3% (95% CI: 0.50–0.97)
Negative predictive value 100% (95% CI: 0.96–1.00)
Overall agreement 98.7%
FISH, fluorescence in situ hybridization; IHC, immunohistochemistry; 
CI, confidence interval.
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consistent with the previous report,27 we observed robust 
FISH signals on the ThinPrep slides, with representation of 
both described FISH patterns (separated green and red signals 
as well as isolated red signals) in the positive cases.
Our consecutive case subseries included nine NSCLC 
specimens positive for ALK rearrangements by ThinPrep-FISH. 
The percentage of ALK-positive samples in our study (9 of 
179, 5% in the consecutive series; 18 of 228, 7.8% overall) 
was within the cited range (2%–13%).4 The increased propor-
tion of positive cases overall compared with the consecutive 
subseries is likely because of the fact that for several patients 
with ALK-positive tumors biopsied before December 2012, 
multiple unique specimens were analyzed.
Because of the high failure of ALK-FISH on cytoblocks 
before the initiation of this study, we used paired ultrasensitive 
IHC as the reference data set. Previous studies conducted by 
us and others demonstrated that ultrasensitive D5F3-IHC for 
ALK has near-perfect correlation with ALK-FISH11,12 and is 
informative in cases with limited tumor cells on the paraffin 
cytoblocks that are otherwise inadequate for FISH testing. In 
the current study, ThinPrep-FISH showed a high correlation 
with ALK-IHC in assessing ALK status, with 100% sensitiv-
ity and 98.6% specificity.
In our study, there were significantly fewer uninformative 
ThinPrep-FISH results because of sample quality or quantity 
when compared with ALK-IHC (0.8% versus 27%, p<0.001). 
Furthermore, in 74 samples with uninformative ALK-IHC and 
successful ThinPrep-FISH, the latter test was positive in six 
cases (8.1%). These data indicate that ThinPrep-FISH can be 
successfully used on cytology samples that are limited or sub-
optimal for cytoblock analysis by FISH or IHC, and may effec-
tively detect a subset of positive cases that would be otherwise 
missed by FISH or IHC analysis on PET material alone.
CONCLUSION
Our results demonstrate that ThinPrep-FISH is feasible 
and can reliably detect ALK gene rearrangements in NSCLC. 
The high concordance between ThinPrep-FISH and  ALK-IHC 
on available cytoblock material warrants the routine use of 
ThinPrep-FISH for the clinical ALK molecular testing in 
NSCLC, especially in cases with limited cytology material.
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